Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAHOGANY: zanubrutinib-based therapy versus lenalidomide plus rituximab in relapsed/refractory follicular or marginal zone lymphoma
NL-OMON58863Phase 3Completed
- Sponsor
- BeOne Medicines
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of zanubrutinib, lenalidomide, rituximab and obinutuzumab in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (4 arms), sponsored by BeOne Medicines. Primary endpoint: Progression-free survival. Started Sep 2023; status: completed.
02
Drugs
zanubrutiniblenalidomiderituximabobinutuzumab
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on NL-OMON58863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58863.